Novel Toll-Like Receptor 4 (TLR4) Inhibitor

Novel potent and selective dual TLR7/8 inhibitor

Novel toll-like receptor 8 (TLR8) inhibitor, potently and selectively reducing TLR8-mediated signaling

The first small molecule inhibitor of translesion synthesis (TLS) that target Rev1-CT

Potent histone methyltransferase inhibitor with rapid antimalarial activity against all blood stage forms in Plasmodium falciparum

Novel inhibitor of both JAK/STAT and proteasome activities, inducing cell death in myeloma cells

Novel inhibitor of plasminogen activator inhibitor-1 (PAI-1)

Penem beta-lactam antibiotic

Novel protease inhibitor (PI) against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, also showing antiviral avtivity as a potential treatment for COVID-19 caused by SARS-CoV-2

Dual Inhibitor of SIRT2 Deacetylase and Defatty-Acylase Activities

Novel degrader of E. coli DHFR (eDHFR), as well as eDHFR-EGFP fusion proteins, demonstrating that degradation does not require covalent attachment of the tag to the target protein

Novel caged protein labeling agent

Allosteric agonist and positive allosteric modulator (PAM) of 5-HT3 receptor

Novel activator of necrostatin-1 sensitive necroptotic cell death, triggering apoptosis, autophagy and necroptosis crosstalk in chronic myeloid leukemia

Novel potent inhibitor of TNF-α

Novel inhibitor of tumor necrosis factor-α (TNF-α)

Emivirine analog with improved activity against drug-resistant HIV mutants

Novel non-nucleoside reverse transcriptase inhibitor of HIV-1

Novel selective inhibitor of TNKS-USP25 interaction, effectively reducing prostate cancer cell proliferation and tumor growth

Novel highly potent and selective TNKS2 inhibitor with antiproliferative effects in a colorectal cancer cell line (DLD-1) where the Wnt pathway is constitutively activated

Highly potent and selective tankyrase inhibitor

Novel potent and selective tankyrase (TNKS) inhibitor

Unique multitargeting drug conjugate with extremely low propensity for development of resistance, targeting RNA polymerase, DNA gyrase, and DNA topoisomerase IV

Novel Human Toll-like Receptor 8-Selective Agonist

Stimulator of metabolism, preventing diseases associated with parturition and peri-partum period, developmental and nutritional disorders in young animals, and bone growth disorders and tetany or paresis caused by calcium, magnesium, and phosphorus metabo

Natural agonist of TPRC1/4/5 channels, also acting as a dual PKCα and PKCθ activator, inducing an insulin resistant phenotype by inhibiting IRS1 and the PI3K/Akt pathway, activating the heat shock factor 1 (HSF1) transcription factor driving glucose depen

Novel dual TOP1 and TDP1 inhibitor, inducing both cellular TOP1cc, TDP1cc formation and DNA damage, resulting in cancer cell apoptosis at a sub-micromolar concentration

Novel narrow spectrum kinase inhibitor, potently inhibiting P38a, Src, and Syk kinase activities

Novel Selective Inhibitor of Endoplasmic Reticulum α-Glucosidase II, Exhibiting Antiflaviviral Activity

Novel highly specific fluorescent TOPK inhibitor

Nucleic acid stain, acting on viable, early apoptotic and necrotic cells differentially, showing specific staining of nuclei without any staining of the cytoplasm

Natural psychoactive agent

Chromogenic peptide substrate for the rapid and specific photometric assay of recombinant hirudin (r-hirudin)

Selective CA IX inhibitor

Novel ToxT inhibitor, reducing Vibrio cholerae virulence in vivo and effectively inhibiting intestinal colonization in the infant mouse

Novel probe for activin receptor-like kinase (ALK4 and ALK5)

Novel inhibitor of O-GlcNAcase (OGA)

Novel probe for CECR2/BPTF bromodomains

First-in-class fluorescent drug delivery vesicle that can efficiently load both water-soluble and -insoluble anticancer drugs

Novel Peripheral Selective Tryptophan Hydroxylase 1 (TPH1) Inhibitor (IC 50 : 42nM) for Obesity and Fatty Liver Disease

Inhibitor of tyrosine recombinases and Holliday junction-resolving enzymes; Antibacterial

Promising amyloid reducing agent by lowering the levels of Aβ.

Novel Specific Inhibitor of Type I Collagen Production in Fibrosis

Novel taxane family member, reducing the brain metastatic colonization of breast cancer cells

Novel tumour progression locus 2 (Tpl2) kinase inhibitor

Enhancer of the cytotoxic effect of immunotoxins (ITs) which results in increased apoptosis in different cancer cells

Mitochondria-activatable luciferin (MAL-Probe)

Novel Type-I Inhibitor of TIE-2

Potent I 2 -imidazoline receptor agonist

Metabolite of Resveratrol

Potent and selective NMDA agonist

Novel HuR binder, modulating HuR-RNA interactions

Novel KGA allosteric inhibitor

Natural resveratrol trimer, acting as a protein kinase C inhibitor

Natural specific inhibitor of γ-secretase, decreasing amyloid-beta levels without influencing cleavage of Notch, showing strong growth inhibitory effects on cancer cell lines and significant anti-complement activity, also acting as a PTP1B inhibitor

Metabolite of Resveratrol

Metabolite of Resveratrol

Novel Highly Selective β2-Adrenoceptor Agonist as an Oral Antiasthmatic Agent

Inhibitor of histone deacetylases

Novel TGR5 agonist, reducing glycemic and dyslipidemic cardiovascular risk in animal models of diabesity

Central sugar signal in plants, regulating sucrose use and allocation, underpinning crop growth and development

Potent and long-acting derivative of the hormone Trenbolone

EC 3.1.1.7 (Acetylcholinesterase) inhibitor, acting as an insecticide, an acaricide, an agrochemical, and a nematicide

AKT Inhibitor, Enhancing Gemcitabine Activity in Pancreatic Cancer Cells

Potent NAE-hydrolyzing acid amidase (NAAA) inhibitor

Metabolite of Trifluoperazine; Antidepressant and antipsychotic

Novel Bromodomain Binding Mimic of Lysine Acetylation

Metabolite of nicotinamide; Specific and potent inhibitor of NNMT, increasing histone methylation at H3K4 and methylated H3K4 occupancy at gene promoters

Antipsychotic and sedative agent as a potent antagonist of H1, 5-HT2A, and alpha1-adrenergic receptors

Specific inhibitor of the histone H3 lysine 9 demethylase KDM4 in HeLa cells.

Copper ion chelator, causing the triple response phenotype by affecting copper ion transport in ethylene signaling from ATX1 to RAN1

Novel anti-secretory and antiulcer agent for treatment of peptic ulcer disease and hypersecretory disorders

First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitor that Overcome Clinically Acquired Resistance

Novel opioid ligand for treatment of overactive bladder, acting as a μ-opioid receptor partial agonist

Novel potent and selective inhibitor of Tropomyosin-related kinase A (TrkA)

First-in-class highly potent and selective inhibitor of TrmD (bacterial t-RNA-(N1G37) methyltransferase)

Potent and selective 5-HT3 receptor antagonist

Serotonin 5-HT3 receptor antagonist

Fluroquinolone antibiotic, suppressing c-Myc transcription and myeloma growth, inhibiting pannexin-1 channels through which ATP is released as find-me signals in apoptotic Jurkat cells

Novel Photosensitive and Photoswitchable TRPA1 Agonist, Optically Control Pain through Channel Desensitization

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

Novel selective inhibitor of the transient receptor potential melastatin 2 (TRPM2) channel, exhibiting TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showing neuroprotective activity in vitro, and significantly reducing ce

Novel agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel

Novel selective TRPV6 inhibitor

Novel TrxR1 inhibitor, selectively killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation

Natural DNA gyrase inhibitor, blocking leukotriene production, inhibiting P-glycoprotein, and showing anti-inflammatory and anti cancer activities

Natural Polycyclic Peptide from a Fungus-Derived Streptomycete

Novel highly selective negative allosteric modulator (NAM) of thyrotropin receptor (TSHR), binding at the ectodomain/TMD interface, between the converging helix, ECL1 and the IA, noncompetitively inhibiting PAM-C2-activation

Novel human thymic stromal lymphopoietin (TSLP) inhibitor

Novel isoform-selective inhibitor of the tumor-associated hCA IX and XII

Novel αvβ3 ligand, disrupting the integrin-MMP2 interaction and showing antiangiogenic activit, inhibiting angiogenesis and tumor growth in vivo

Novel antagonist of T-type calcium channels

First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 1.7 nM

First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 3.1 nM

Novel transthyretin (TTR) stabilizer, binding to the T4 binding pocket of TTR and preventing the dissociation of TTR to monomer

FLT3 Kinase Inhibitor, Overcoming Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia

LpxC substrate-analog inhibitor

Novel inhibitor of tubulin polymerization and caused HepG2 cells arrest in G2/M phase

Novel potent tubulin polymerization inhibitor, forming stable interactions in the colchicine-binding site of tubulin, showing significant antiproliferative activities on a panel of tumor cell lines

Novel allosteric modulator of free fatty acid receptor 3 (FFA3, previously GPR41)

Novel allosteric modulator of free fatty acid receptor 3 (FFA3, previously GPR41)

Long-acting beta2-adrenergic receptor agonist

Novel Inhibitor of Metastatic Cancer Cell Migration and Invasion

Antibiotic, inhibiting the first step in the N-linked glycosylation in eukaryotes and inducing ER stress to activate the unfolded protein response (UPR)

Inhibitor of bacterial biofilm formation in Staphylococcus epidermidis

Natural potent porcine pancreatic elastase (PPE) inhibitor

Novel anticancer agent, affecting steroid biosynthesis, increasing RagD expression, and causing abnormal cellular cholesterol localization

Novel disruptor of the bacterial protein, FtsZ

Chymase inhibitor, preventing the development and progression of non-alcoholic steatohepatitis, improving vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats

Novel highly potent and selective TYK2 JH2 inhibitor, providing robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model

First-in-class selective PRMT5 inhibitor, blocking EBV-driven B lymphocyte transformation and survival while leaving normal B cells unaffected

Stable analog of phosphotyrosine (pTyr)

Novel competitive inhibitor of tyrosinase enzyme

Potent and selective dopamine D4 receptor antagonist

Novel potent inhibitor of microtubule polymerization, binding directly to tubulin α/β heterodimers via the colchicine-binding site, perturbing mitotic spindles, delaying cells in mitosis and promotes apoptosis

Novel potent and broad-spectrum antiviral agent against multiple strains of EV-D68, EV-A71, and CVB3, targeting the viral protein 2C

Selective modulator of NMDA_receptor>NMDA receptors, potentiates responses at GluN1/GluN2A

Novel pan-inhibitor of GluN1/GluN2 receptors

Novel pan potentiator of GluN1/GluN2 receptors

Novel NMDAR positive allosteric modulator (PAM), robustly potentiating responses at all GluN1/GluN2 subtypes and at neuronal NMDARs

Novel Antagonist of the USP5 Zinc Finger Ubiquitin-Binding Domain (USP5 ZnF-UBD)

Modulator of cyclic AMP generation, amplifing induced cyclic AMP formation in rat brain tissue; Nootropic

Potent ligand of synaptic vesicle protein 2A (SV2A)

Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins

Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins

Novel allosteric modulator of neonatal Fc receptor (FcRn), binding to the extracellular domain of FcRn

Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3

Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3

Competitive dual inhibitor of the hydrolysis FS-3 and the phosphodiesterase substrate p-nitrophenyl thymidine 5'-monophosphate

Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors

Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors

Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors

Histamine H3 Receptor Antagonist in Treatments of Cognition Disorders

The first potent nonimidazole H3 receptor antagonist (pKi=8.40)

Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), Showing Efficacy in Neuropathic Pain Amelioration

Novel potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor, improving survival in Ras-driven acute myeloid leukemia

Dual inhibitor of fatty acid amide hydrolase (FAAH) and α/β hydrolase domain 6 (ABHD6)

Stereoisomer of UCN-01, inhibiting protein kinase C with a slightly reduced potency than UCN-01

Novel dual inhibitor of dihydrofolate reductase (DHFR) and its functional analog, Rv2671

Fluorescent excitatory amino acid transporter subtype 1 (EAAT1) selective inhibitor

Potent and selective 11ß-HSD1 inhibitor, improving memory, including after intracerebroventricular drug administration to the central nervous system alone

Novel selective delta-opioid receptor agonist

Novel Nicotinic Acetylcholine Receptor Antagonist, Inhibiting Nicotine Reward and Decreases Anxiety and Decreasing Ethanol Intake in Alcohol-Preferring Rats

Novel inhibitor of UGM, impeding C. glutamicum growth

Novel inhibitor of UGM, impeding C. glutamicum growth

Novel potent human immunodeficiency virus type 1 (HIV-1) protease inhibito

Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD)

Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD)

Potent VMAT2 inhibitor

Novel chemically stable fluorescent marker of the ureter

Novel Vaccine Adjuvant for Mycobacterium tuberculosis

Novel potent and selective dual PLK1 and BRD4 inhibitor, inducing apoptosis in pediatric tumor cell lines, leading to significant tumor regression

Novel, Potent, and Selective CBP/P300 Inhibitor

Novel Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitor

Novel anti-virulence agent, rescuing nematodes from a Staphylococcus aureus infection and preventing the formation of biofilm in a dose-dependent manner without interfering with bacterial viability

Novel fluorescent UnaG ligand, binding UnaG with high affinity (Kd = 3 nM) to induce a 2.5-fold fluorescence intensity enhancement and a 10 nm red shift

Novel nonhematotoxic DNA intercalating agent with potent antitumor activity, inducing apoptosis via inhibition of key proteins in the PI3K/Akt/mTOR signaling pathway

UNC0737 is a negative control of UNC0638 and the N-methyl analog of UNC0638. UNC0737 was designed to eliminate the hydrogen bond interaction seen in the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino group at the 4-position of UNC0224's quinazoline ring3. UNC0737 was >300-fold less potent than UNC0638 in G9a and GLP biochemical assays. As expected, UNC0737 was a poor inhibitor of G9a (IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled assays.

Biotinylated UNC0638, enabling chemiprecipitation of G9a from whole cell lysates

Novel MYC protein stablizer, increasing the abundance of endogenous MYC proteintargeting the receptor tyrosine kinases KIT and platelet-derived growth factor receptor α (PDGFRα)

Novel inhibitor of ROP18, inhibiting ROP18 within cells, and abrogating its effects on the host IRG pathway

Novel Peptide Inhibitor for Calcium and Integrin Binding Protein 1 (CIB1)

Negative control for UNC1666 which is a dual Mer and Flt-3 tyrosine kinase inhibitor

Orally Active Adenosine A 1 Receptor Agonist

Novel Ligand of EEDm acting as an allosteric inhibitor of PRC2

Novel allosteric inhibitor of PRC2 catalytic activity

Novel allosteric inhibitor of PRC2 catalytic activity

Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT

Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

Novel peptidomimetic antagonist of the PHF1 Tudor domain, binding both PHF1 Tudor domain and the related protein PHF19

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

Novel potent and selective PAM of CBX8, blocking H3K27me3 binding and enhancing CBX8 affinity for nucleic acids, evicting PRC1 from H3K27me3 targets triggering DLBCL cell differentiation

Novel β-arrestin-biased D2 receptor (D2R) agonist

Novel Eph antagonist, inhibiting Eph/ephrin interactions, enhancing glucose-stimulated insulin secretion (GSIS), and acting as a hypoglycemic agent

The first bifunctional (chemoreactive and clickable) probe for Adenosine A1 and A3 Receptors

Potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor

Novel superagonist of the urotensin-II (UT) receptor

Novel Potent antagonist of the Urotensin-II (UT) Receptor

Novel superagonist of the urotensin-II (UT) receptor

Novel potent antagonist of the Urotensin-II (UT) receptor

Novel E-Selectin antagonist, disrupting cell survival pathway activation, enhancing chemotherapy response and protecting from toxicity such as mucositis with improved survival in vivo

Novel Neuropeptide Y Y4 Receptor (Y4R) Antagonist (pK i values <7.57)

Novel Potent Neuropeptide Y Y4 Receptor (Y4R) Partial Agonist (pK i : 8.47)

Natural flavonoid from the leaves of Glycyrrhiza uralensis

Novel Red-Emitting Fluorescent Dualsteric Probe for the Muscarinic Acetylcholine M2 Receptor

Novel FAAH inhibitor

Potent, selective, and irreversible inhibitor of fatty acid amide hydrolase (FAAH)

Novel potent partial agonist of histamine H4 receptors (H4R)

Novel potent partial agonist of histamine H4 receptors (H4R)

Py-5-Labeled Fluorescent Multipurpose Probe for Investigations on the Histamine H3 and H4 Receptors, acting as a partial agonist at the hH3R [pEC50 (reporter gene) 8.77] and as an inverse agonist/antagonist at the h/mH4Rs [pIC50 (reporter gene) 8.76/7.08;

Novel subtype selective histamine H2 receptor G protein-biased agonist

Novel H2 receptor agonist, functionally stimulating human cardiac H2 receptors in vitro and in vivo

Novel H2 receptor agonist, functionally stimulating human cardiac H2 receptors in vitro and in vivo

Novel NPY Y1 Receptor Antagonist

Novel fluorescent histamine H3 receptor ligand

Novel H2 receptor agonist, functionally stimulating human cardiac H2 receptors in vitro and in vivo